Status: Recruiting
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Participants needed: 42
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Verismo TherapeuticsUpdated: Jun 24, 2026Locations: 5
Eligibility criteria
Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary... [+5]
Active invasive cancers other than mesothelioma, cholangiocarcinoma, and ovarian... [+6]